These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 8222870)
1. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. Scaglione F; Demartini G; Dugnani S; Fraschini F Chemotherapy; 1993; 39(6):416-23. PubMed ID: 8222870 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of macrolides against intracellular Legionella pneumophila. Segreti J; Meyer P; Kapell K Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407 [TBL] [Abstract][Full Text] [Related]
3. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530 [TBL] [Abstract][Full Text] [Related]
4. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. Burgess DS; Hastings RW; Horan JL Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial resistance of Staphylococcus aureus and oral streptococci strains from high-risk endocarditis patients. Groppo FC; Castro FM; Pacheco AB; Motta RH; Filho TR; Ramacciato JC; Florio FM; Meechan JG Gen Dent; 2005; 53(6):410-3. PubMed ID: 16366048 [TBL] [Abstract][Full Text] [Related]
6. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Lemaire S; Van Bambeke F; Tulkens PM Antimicrob Agents Chemother; 2009 Sep; 53(9):3734-43. PubMed ID: 19564365 [TBL] [Abstract][Full Text] [Related]
8. The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo. Jonas D; Engels I; Daschner FD; Frank U J Antimicrob Chemother; 2000 Sep; 46(3):385-90. PubMed ID: 10980164 [TBL] [Abstract][Full Text] [Related]
9. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes. De Vecchi E; Nicola L; Zucchetti E; Drago L J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793 [TBL] [Abstract][Full Text] [Related]
10. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. Anderson R; Joone G; van Rensburg CE J Antimicrob Chemother; 1988 Dec; 22(6):923-33. PubMed ID: 2977384 [TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of azithromycin in against intracellular Helicobacter pylori. Hulten K; Cars O; Hjelm E; Engstrand L J Antimicrob Chemother; 1996 Mar; 37(3):483-9. PubMed ID: 9182105 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. Fietta A; Merlini C; Gialdroni Grassi G J Chemother; 1997 Feb; 9(1):17-22. PubMed ID: 9106013 [TBL] [Abstract][Full Text] [Related]
13. In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates. Drago L; De Vecchi E; Nicola L; Legnani D; Prenna M; Ripa S J Chemother; 2005 Apr; 17(2):161-8. PubMed ID: 15920900 [TBL] [Abstract][Full Text] [Related]
14. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. Lemaire S; Van Bambeke F; Tulkens PM Int J Antimicrob Agents; 2011 Jul; 38(1):52-9. PubMed ID: 21596526 [TBL] [Abstract][Full Text] [Related]
15. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. Carbon C; Poole MD J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741 [TBL] [Abstract][Full Text] [Related]
16. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Hultén K; Rigo R; Gustafsson I; Engstrand L Antimicrob Agents Chemother; 1996 Dec; 40(12):2727-31. PubMed ID: 9124830 [TBL] [Abstract][Full Text] [Related]
17. An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus. Anderson R; Joone G; van Rensburg CE J Infect Dis; 1986 Mar; 153(3):593-600. PubMed ID: 3950443 [TBL] [Abstract][Full Text] [Related]
18. Effect of minor pH changes on the in-vitro activity of azithromycin and clarithromycin. Fuchs PC; Barry AL; Brown SD J Antimicrob Chemother; 1997 Jan; 39(1):109-10. PubMed ID: 9044039 [No Abstract] [Full Text] [Related]
19. Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. Martin SJ; Pendland SL J Antimicrob Chemother; 1998 Jun; 41(6):643-8. PubMed ID: 9687103 [TBL] [Abstract][Full Text] [Related]
20. Primary resistance and antibiotic minimum inhibitory concentrations for Helicobacter pylori strains, in Split, Croatia. Tonkić M; Tonkić A; Goić-Barisić I; Jukić I; Simunić M; Punda-Polić V J Chemother; 2006 Aug; 18(4):437-9. PubMed ID: 17024803 [No Abstract] [Full Text] [Related] [Next] [New Search]